CUSTOM CURESPERSONALIZED MEDICINE
With adverse effects of prescribed drugs being a leading cause of preventable death in the U.S., providing the right drug to the right person at the right time is one of the holy grails of medicine. Physicians scrutinizing our genes before they read our charts is the new era of personalized medicine. Medicine is already distancing itself from the traditional approach that prescribes treatment based on population averages. Cancer therapies are being calibrated to target specific strains of cancers and how they affect specific patients. By following paths laid down by genetic markers, researchers are working to customize more effective therapies for diseases.
PEOPLE WILL BE AFFECTED BY DEMENTIA BY 2050
NUMBER OF AMERICANS WHO WILL BE LIVING WITH ALZHEIMER'S DISEASE BY 2050
THE COST OF SEQUENCING A PERSON'S GENOME IN THE NEXT DECADE
THE SPACE REQUIRED TO HOLD THE POLISHED VERSION OF A PERSON'S GENETIC CODE
Arizona scientists are targeting advanced therapies that could prevent Alzheimer’s and revolutionize treatments for nearly 50 million inflicted with dementia worldwide.
Hospitals, research centers and biotech companies around our state are developing new diagnostic technologies. They are investigating protein biomarkers as indicators of individual health. They are standardizing the techniques used to identify these markers quickly and economically by examining large numbers of samples with robotic lab machinery. Storage and computational capabilities in a genome cloud will enable virtual experiments and information sharing, while other companies are developing methods to process the terabytes of medical data generated by monitoring devices and genetic testing.
This concentration of biotech players means Arizona’s innovators are well ahead of the game, mapping the molecular signature of diseases and developing molecular diagnostics to identify which patients will benefit from improved therapies. Our universities and private research institutions and world-class medical institutions are teaming up to use molecular and genomic data to discover the mechanisms of disease – leading to new ways to diagnose patients and tailor individual treatments.